​

Allogene Therapeutics (ALLO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ALLO Stock Forecast

Allogene Therapeutics (ALLO) stock forecast, based on 26 Wall Street analysts, predicts a 12-month average price target of $29.00, with a high of $55.00 and a low of $7.00. This represents a 1900.00% increase from the last price of $1.45.

- $11 $22 $33 $44 $55 High: $55 Avg: $29 Low: $7 Last Closed Price: $1.45

ALLO Stock Rating

Allogene Therapeutics stock's rating consensus is Buy, based on 26 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 19 Buy (73.08%), 7 Hold (26.92%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 26 7 19 0 Strong Sell Sell Hold Buy Strong Buy

ALLO Price Target Upside V Benchmarks

TypeNameUpside
StockAllogene Therapeutics1900.00%
SectorHealthcare Stocks 35.94%
IndustryBiotech Stocks 83.61%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$8.00
Last Closing Price$1.45$1.45$1.45
Upside/Downside--451.72%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25583--16
Mar, 25485--17
Feb, 25485--17
Jan, 25485--17
Dec, 24495--18
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 16, 2024Debjit ChattopadhyayH.C. Wainwright$9.00$2.98202.01%520.69%
May 14, 2024Kalpit PatelB.Riley Financial$7.00$2.90141.38%382.76%
Jun 13, 2022Jack AllenRobert W. Baird$11.00$9.7412.94%658.62%
Jan 03, 2022Michael SchmidtGuggenheim$35.00$15.29128.91%2313.79%
Dec 03, 2021John NewmanCanaccord Genuity$55.00$17.62212.15%3693.10%
Oct 08, 2021Mark BreidenbachOppenheimer$40.00$13.13204.65%2658.62%
Oct 08, 2021Jason GerberryBank of America Securities$32.00$13.13143.72%2106.90%
Oct 08, 2021Biren AminJefferies$30.00$13.13128.48%1968.97%
Oct 08, 2021Anthony ButlerRoth Capital$35.00$13.13166.57%2313.79%
Sep 23, 2021Dane LeoneRaymond James$36.00$27.6430.25%2382.76%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 30, 2024H.C. WainwrightBuyBuyhold
Aug 09, 2024CitigroupBuyBuyhold
Jun 17, 2024Piper SandlerOverweightOverweighthold
May 31, 2024Piper SandlerUnderperformUnderperformhold
May 31, 2024Piper SandlerOverweightinitialise
May 21, 2024OppenheimerOutperformOutperformhold
May 16, 2024H.C. WainwrightBuyBuyhold
May 15, 2024RBC CapitalBuyBuyhold
Jan 06, 2023Robert W. BairdOutperformupgrade
Dec 13, 2022Bank of America SecuritiesReducedowngrade

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.94$-1.80$-2.30$-2.09$-1.32----
Avg Forecast$-2.12$-1.96$-2.37$-2.01$-1.33$-1.35$-1.45$-1.51$-0.85
High Forecast$-0.80$-0.74$-1.00$-1.89$-1.27$-1.02$-0.95$-0.91$-0.40
Low Forecast$-3.20$-2.96$-2.71$-2.16$-1.43$-1.67$-2.01$-2.46$-1.05
Surprise %-8.49%-8.16%-2.95%3.98%-0.75%----

Revenue Forecast

$0 $60M $120M $180M $240M $300M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$38.49M$243.00K$95.00K$22.00K----
Avg Forecast$2.93M$38.32M$177.95K$134.71K$23.75K$26.67K$11.11K$46.00M$240.57M
High Forecast$3.52M$53.31M$197.72K$149.67K$39.58K$31.37K$13.07K$47.57M$283.03M
Low Forecast$2.35M$19.99M$98.86K$104.77K$7.92K$15.69K$6.54K$44.43M$141.51M
Surprise %-0.45%36.55%-29.48%-7.37%----

Net Income Forecast

$-400M $-330M $-260M $-190M $-120M $-50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-233.47M$-244.84M$-329.81M$-327.26M$-257.59M----
Avg Forecast$-264.99M$-275.94M$-300.14M$-327.26M$-212.17M$-210.95M$-232.82M$-336.34M$-133.39M
High Forecast$-211.99M$-220.75M$-240.11M$-261.81M$-199.87M$-160.57M$-149.45M$-142.92M$-61.99M
Low Forecast$-317.99M$-331.13M$-360.17M$-392.72M$-224.47M$-261.32M$-316.20M$-385.39M$-163.99M
Surprise %-11.89%-11.27%9.89%-21.41%----

ALLO Forecast FAQ

Is Allogene Therapeutics stock a buy?

Allogene Therapeutics stock has a consensus rating of Buy, based on 26 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 19 Buy, 7 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Allogene Therapeutics is a favorable investment for most analysts.

What is Allogene Therapeutics's price target?

Allogene Therapeutics's price target, set by 26 Wall Street analysts, averages $29 over the next 12 months. The price target range spans from $7 at the low end to $55 at the high end, suggesting a potential 1900.00% change from the previous closing price of $1.45.

How does Allogene Therapeutics stock forecast compare to its benchmarks?

Allogene Therapeutics's stock forecast shows a 1900.00% upside, outperforming the average forecast for the healthcare stocks sector (35.94%) and outperforming the biotech stocks industry (83.61%).

What is the breakdown of analyst ratings for Allogene Therapeutics over the past three months?

  • April 2025: 31.25% Strong Buy, 50.00% Buy, 18.75% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 23.53% Strong Buy, 47.06% Buy, 29.41% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 23.53% Strong Buy, 47.06% Buy, 29.41% Hold, 0% Sell, 0% Strong Sell.

What is Allogene Therapeutics’s EPS forecast?

Allogene Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.35, marking a 2.27% increase from the reported $-1.32 in 2024. Estimates for the following years are $-1.45 in 2026, $-1.51 in 2027, and $-0.85 in 2028.

What is Allogene Therapeutics’s revenue forecast?

Allogene Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $26.67K, reflecting a 21.21% increase from the reported $22K in 2024. The forecast for 2026 is $11.11K, followed by $46M for 2027, and $240.57M for 2028.

What is Allogene Therapeutics’s net income forecast?

Allogene Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-211M, representing a -18.11% decrease from the reported $-258M in 2024. Projections indicate $-233M in 2026, $-336M in 2027, and $-133M in 2028.